The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therapy in First-line H. Pylori Eradication

NCT04527055 · clinicaltrials.gov ↗

PHASE4

Phase

ENROLLING_BY_INVITATION

Status

312

Enrollment

OTHER

Sponsor class

Conditions

Helicobacter Pylori Infection
Dysbiosis
Probiotics

Interventions

DRUG: Bismuth Subcitrate 120 MG Oral Tablet
DIETARY_SUPPLEMENT: Lactobacillus acidophilus and Bifidobacterium lactis Bb12
DRUG: Esomeprazole 40mg
DRUG: Metronidazole 250 MG
DRUG: Tetracycline Pill

Sponsor

National Cheng-Kung University Hospital